U.S. Personal Products Stock News

NasdaqGS:CNDT
NasdaqGS:CNDTProfessional Services

Assessing Conduent (CNDT) Valuation After Insider Buying And EBITDA Margin Progress

Why insiders are buying Conduent stock after recent EBITDA progress Recent insider share purchases at Conduent (CNDT), including buying by the CEO and a director, have drawn attention as the company reports higher full year 2025 adjusted EBITDA and improved margins despite lower revenue. See our latest analysis for Conduent. The insider buying comes after a sharp move in the 1 day share price return of 11.19% and a 7 day gain of 3.58%, although the 1 year total shareholder return of 57.6% and...
NasdaqGS:CAI
NasdaqGS:CAIBiotechs

A Look At Caris Life Sciences (CAI) Valuation After Recent Share Price Weakness

Caris Life Sciences: Event Context and Recent Share Performance Caris Life Sciences (CAI) has drawn investor attention recently as its share price has moved from a last close of US$19.53 while posting negative returns over the past week, month, and past 3 months. See our latest analysis for Caris Life Sciences. The recent 1 day share price return of a 6.33% decline, alongside a 30 day share price return of a 21.88% decline and year to date share price return of a 27.61% decline, suggests...
NYSE:SFL
NYSE:SFLOil and Gas

Does SFL’s Maintained Dividend Amid Net Losses Change The Bull Case For SFL (SFL)?

SFL Corporation Ltd. declared a quarterly cash dividend of US$0.20 per share, paid on or around March 30, 2026, to shareholders of record as of March 12, 2026, and also reported fourth-quarter 2025 revenue of US$175.51 million alongside a net loss of US$4.65 million. Despite reporting a full-year 2025 net loss of US$26.43 million, SFL sustained its US$0.20 dividend for an 88th consecutive payout, underlining management’s emphasis on ongoing cash returns. We will now examine how SFL’s...
NasdaqGS:ONB
NasdaqGS:ONBBanks

Is Board Downsizing And A Higher Dividend Altering The Investment Case For Old National Bancorp (ONB)?

Old National Bancorp recently announced that four directors, including long-serving members reaching the age limit, will retire at the May 2026 annual meeting, while the board has amended its bylaws to allow flexible board sizing and plans to shrink from 16 to 12 members. At the same time, the company raised its quarterly common dividend by 3.6% to US$0.145 per share and affirmed preferred dividends, underscoring an emphasis on capital returns alongside governance changes and ongoing...
NasdaqGS:CHEF
NasdaqGS:CHEFConsumer Retailing

The Bull Case For Chefs' Warehouse (CHEF) Could Change Following Strong Q4 Beat And Cautious M&A Shift

In February 2026, The Chefs’ Warehouse reported fourth-quarter 2025 sales of US$1,142.56 million, with full-year sales reaching US$4.15 billion and net income of US$72.36 million, while management highlighted strong demand in upscale-casual and higher-end dining channels. Executives also indicated they are actively evaluating accretive, low-risk acquisitions that could complement existing territories and enhance organic growth, while carefully weighing these options against potential share...
NYSE:RL
NYSE:RLLuxury

Upgraded 2026 Revenue Outlook Might Change The Case For Investing In Ralph Lauren (RL)

Earlier in February 2026, Ralph Lauren reported a strong fiscal Q3 holiday quarter, with double-digit revenue growth and demand holding up across regions, and management lifted its full-year 2026 constant-currency revenue outlook to high-single to low-double digit growth. These results have reinforced confidence in Ralph Lauren’s ability to sustain its premium positioning while capturing growth through brand strength, product mix and broader geographic reach. We’ll now explore how this...
NasdaqCM:CELC
NasdaqCM:CELCBiotechs

Is Celcuity’s (CELC) New Board Appointment a Turning Point for Its Commercial Strategy?

Celcuity Inc. recently appointed Charles (Chip) R. Romp, a veteran oncology-focused pharmaceutical executive and current CEO of Secura Bio, to its Board of Directors, adding more than 25 years of commercial and sales leadership experience to the company. Romp’s track record helping build commercial franchises for oncology drugs at Seagen and Genentech adds board-level insight that aligns directly with Celcuity’s focus on bringing targeted cancer therapies to market. We’ll now look at how...
NasdaqGS:QURE
NasdaqGS:QUREBiotechs

Evaluating uniQure (QURE) After New Class Action Allegations Over AMT-130 FDA Disclosures

Why the new class action matters for uniQure investors Kessler Topaz Meltzer & Check has filed a securities fraud class action against uniQure (NasdaqGS:QURE), alleging misleading statements about FDA alignment and timelines for AMT-130, its Huntington’s disease gene therapy program. See our latest analysis for uniQure. uniQure’s latest share price of US$23.43 comes after a 7 day share price return of 14.29%. However, the 90 day share price return of a 15.66% decline and 5 year total...
NasdaqGS:METC
NasdaqGS:METCMetals and Mining

A Look At Ramaco Resources (METC) Valuation After Recent Share Price Pullback

Ramaco Resources (METC) has been drawing attention after a sharp decline in its share price over the past month, even as its past 3 months return, one year total return, and longer term performance figures remain positive. See our latest analysis for Ramaco Resources. The recent 40.26% 1 month share price decline to US$16.56 sits against a much stronger backdrop, with a 1 year total shareholder return of 73.74% and multi year total shareholder returns still firmly positive. This suggests...
NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

Orrum Data Partnership Might Change The Case For Investing In LivaNova’s Digital Strategy (LIVN)

Orrum Clinical Analytics recently announced a partnership with LivaNova USA Inc. to link LivaNova’s Essenz Perfusion System with Orrum’s CORE Insights platform, enabling automatic transfer of perfusion case data for post-operative analysis and peer benchmarking. By extending Essenz data into a secure analytics environment that supports evidence-based performance improvement, the collaboration could strengthen LivaNova’s positioning in data-driven cardiopulmonary care and potentially appeal...
NYSE:OPLN
NYSE:OPLNCommercial Services

How OPENLANE’s 2026 Profit Outlook Versus 2025 Loss Per Share At OPENLANE (OPLN) Has Changed Its Investment Story

In February 2026, OPENLANE, Inc. reported full-year 2025 results showing revenue of US$1.93 billion and net income of US$177.7 million, while also recording a basic and diluted loss per share of US$0.96 from continuing operations. The company also issued 2026 guidance calling for income of US$130 million to US$147 million and diluted net income per share of US$0.95 to US$1.09, sharpening investor focus on how its mix of continuing and discontinued operations affects reported...
NYSE:HIG
NYSE:HIGInsurance

Assessing Hartford Insurance Group (HIG) Valuation After Recent Share Price Momentum

Event context and recent performance Hartford Insurance Group (HIG) has drawn fresh investor attention after a recent price move, with the stock closing at $142.19. That sits alongside a 10.6% return over the past month and 4.1% over the past 3 months. See our latest analysis for Hartford Insurance Group. Zooming out, Hartford Insurance Group’s recent 1 day and 1 month share price gains sit against a year to date share price return of 3.7%, while its 1 year total shareholder return is 29.8%...
NYSE:OVV
NYSE:OVVOil and Gas

Is It Too Late To Consider Ovintiv (OVV) After The Recent Share Price Surge?

If you are wondering whether Ovintiv's share price still offers value at current levels, it helps to step back and look at what the market might be pricing in. The stock closed at US$50.58, with returns of 7.8% over the last 7 days, 23.3% over the last 30 days, 24.9% year to date, 20.3% over 1 year, 20.9% over 3 years, and 147.0% over 5 years. Recent news around Ovintiv has largely focused on its position in the US energy sector and how investors are weighing commodity price moves against...
NasdaqGS:IDXX
NasdaqGS:IDXXMedical Equipment

Is IDEXX’s (IDXX) Board Transition Shaping Its Strategy Around InVue DX and Recurring Revenue?

In February 2026, IDEXX Laboratories announced that long-serving director M. Anne Szostak will retire from the Board after the 2026 Annual Meeting, with no disagreements cited and the Class III board size reduced upon her departure while overall board size is maintained through the previously announced appointment of Michael G. Erickson, PhD, as a Class II director. This board transition comes as IDEXX benefits from strong recurring revenue, ongoing earnings outperformance, and growing...
NYSE:BIRK
NYSE:BIRKLuxury

Is Birkenstock Holding (BIRK) Now Offering A Discount After Post‑Listing Share Price Slide

If you are wondering whether Birkenstock Holding is fairly priced or offering value right now, this article will walk through what the current numbers actually say about the stock. At a last close of US$40.89, the shares show a 2.7% return over the past 7 days, 3.4% over the last 30 days, and a 2.1% decline year to date, with a 21.1% decline over the past year adding extra interest around where value might sit today. Recent coverage has focused on Birkenstock Holding as a listed footwear...
NYSE:WRBY
NYSE:WRBYSpecialty Retail

Does Warby Parker's New CFO Reframe WRBY's Balance Between Innovation, Margins, and Growth Ambitions?

Earlier in February 2026, Warby Parker appointed Adrian Mitchell, a veteran retail executive and former Macy’s COO and CFO, as its new Chief Financial Officer, with Mitchell also becoming the company’s principal financial and accounting officer while co-founder Dave Gilboa continues as Co-CEO. Mitchell’s mix of retail operations, consulting, and board-level experience in consumer brands may be particularly relevant as Warby Parker scales new initiatives like AI glasses and expanded eye-care...
NYSE:CTOS
NYSE:CTOSTrade Distributors

Is Hiab’s Expanded Distribution Deal Reframing the Diversification Story for Custom Truck One Source (CTOS)?

On 11 February 2026, Hiab announced a dealer agreement with Custom Truck One Source to expand sales and service coverage for HIAB loader cranes across 12 U.S. states and MOFFETT truck mounted forklifts across eight states. This agreement meaningfully broadens Custom Truck’s access to crane and forklift customers in key Western and Northeastern regions, deepening its role as an equipment solutions provider for infrastructure-related industries. We’ll now examine how this expanded Hiab...
NasdaqGS:IDCC
NasdaqGS:IDCCSoftware

Is It Too Late To Consider InterDigital (IDCC) After 73% Surge And Licensing Headlines?

If you are looking at InterDigital and wondering whether the recent share price really reflects its underlying worth, you are not alone. The stock last closed at US$358.50, with a 1 year return of 72.7% and a 3 year return that is more than 4x, even after a 4.4% pullback over the past week and an 8.5% gain across the last 30 days. Recent news coverage has focused on InterDigital’s role in wireless and video technology licensing and its activity in intellectual property agreements. This helps...
NYSE:CBRE
NYSE:CBREReal Estate

CBRE Expands Data Center Reach As Valuation Lags Analyst Targets

CBRE Group (NYSE:CBRE) has acquired Pearce Services, expanding its reach in data center solutions. The deal adds field services and technical capabilities that support data center operations. CBRE continues to invest in AI and technology to improve service delivery and efficiency. These moves come as companies face macroeconomic challenges and look to outsource more real estate and technical functions. CBRE Group, a global commercial real estate services firm, now has an expanded foothold...
NYSE:MPT
NYSE:MPTHealth Care REITs

How Earnings Beat, Lease Resets, and Dividend at Medical Properties Trust (MPT) Has Changed Its Investment Story

In February 2026, Medical Properties Trust reported fourth-quarter and full-year 2025 results showing higher sales and revenue, a swing from a very large prior-year loss to US$17.31 million in quarterly net income, and normalized funds from operations of US$0.18 per share that exceeded analyst expectations. The REIT also largely resolved its exposure to Prospect Medical Holdings’ bankruptcy through a new 15-year lease on six California hospitals, restructured its Vibra Healthcare...
NasdaqGS:KDP
NasdaqGS:KDPBeverage

Is It Time To Reassess Keurig Dr Pepper (KDP) After Recent Share Price Recovery

Wondering if Keurig Dr Pepper at around US$29.54 is offering fair value or a potential opportunity? This article walks you through what the current price could be telling you. The stock has seen a 6.4% gain over the last 30 days and 6.5% year to date, but that sits against a 10.5% decline over the past year and a 9.6% gain across five years. Recent coverage of Keurig Dr Pepper has focused on its position in the US beverages and coffee market and how it fits into broader consumer staples...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Praxis Precision Medicines Nears First Neurology Launches With Dual NDA Filings

Praxis Precision Medicines (NasdaqGS:PRAX) has submitted two NDAs for ulixacaltamide and relutrigine, moving its lead programs toward potential commercialization. The FDA has granted breakthrough therapy designation to ulixacaltamide, signaling regulatory focus on the drug's potential for patients with neurological disorders. The NDAs are supported by positive Phase III data, and the company is preparing for its first commercial launches, with additional pivotal readouts planned for...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Why Grab Holdings (GRAB) Is Up 6.1% After First Profitable Year And $500 Million Buyback

Grab Holdings reported its 2025 results, delivering breakeven fourth-quarter earnings, full-year net income of US$268 million on sales of US$3.37 billion, alongside a new US$500 million share repurchase program and plans to adopt a Third Amended and Restated Memorandum and Articles of Association following a March 24, 2026 EGM. The company also marked its first full year of net profitability, while using its improved cash position to fund buybacks and expand into international wealth...
NasdaqGS:FFBC
NasdaqGS:FFBCBanks

Assessing First Financial Bancorp (FFBC) Valuation After Recent Share Price Momentum

First Financial Bancorp (FFBC) has attracted fresh attention after a period of solid share performance, with recent returns over the past month and past 3 months prompting a closer look at how the bank’s fundamentals compare. See our latest analysis for First Financial Bancorp. At a share price of $30.36, First Financial Bancorp’s recent momentum is reflected in a 30 day share price return of 13.11% and a 90 day share price return of 24.94%. The 1 year total shareholder return of 16.58%...